The company was formed in 2008 through a management buyout of the active pharmaceutical ingredients business of Alpharma Inc. (now part of New York-based Pfizer Inc

The company was formed in 2008 through a management buyout of the active pharmaceutical ingredients business of Alpharma Inc. (now part of New York-based Pfizer Inc

A couple of hours later, it edged up further after New York-based Royalty Pharma upped its bid for the company

Most of Actavis' sales, at this point, derive from generic therapies, including major revenue generators such as those for New York-based Pfizer Inc.'s cholesterol-buster Lipitor (atorvastatin), and for Concerta (methylphenidate hydrochloride), the compound for attention-deficit and hyperactivity disorder from Johnson & Johnson, of New Brunswick, N.J

Intercept Pharmaceuticals Inc., of New York, reported initial results from OBADIAH, an ongoing Phase IIa trial of obeticholic acid (OCA) as a treatment for primary bile acid diarrhea (PBAD), showing that treatment with OCA is associated with statistically significant increased levels of fibroblast growth factor 19 (FGF19) and improvement in clinical symptoms in patients with PBAD

A couple of hours later, it edged up further after New York-based Royalty Pharma upped its bid for the company

Relmada Therapeutics Inc., of New York, retained Brio Financial Group and GBH CPAs PC as financial reporting consultant and audit firms, respectively, to prepare for a public listing

Inc. (Whitehouse Station, N.J.) Bristol-Myers Squibb Co. (New York) ND Nonexclusive deal to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus Merck will conduct the trial 4/23/13 Merck KGgA (Darmstadt, Germany) Pfizer Inc. (New York) ND Extended collaboration signed in 2002 by Merck's subsidiary EMD Serono Inc...Inc. (Whitehouse Station

it also gets research funding and royalties, while BMS holds onto worldwide rights 4/17/13 Tetragenetics Inc. (Cambridge, Mass.) Pfizer Inc. (New York) ND Deal with an option for an exclusive license with Pfizer using Tetragenetics' SionX application of its discovery platform Financial terms were not disclosed 4/4/13 X-BODY Biosciences Inc. (Waltham, Mass.) Jiangsu Hengrui Medicine Co...Merck gains worldwide commercialization rights and will pay royalties to Abide 5/3/13 Adaptive Biotechnologies

In 2007, the company inked a blockbuster deal with Pfizer Inc., of New York, focused on its Gene Expression Modulation by Small-molecules (GEMS) technology platform, which identifies small molecules that regulate post-transcriptional control mechanisms

Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs

Intra-Cellular Therapies Inc., of New York, added Michael Rawlins to its board...Ohr Pharmaceutical Inc., of New York, added Thomas M. Riedhammer to its board

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

That position, taken together with this latest deal, points to a possible future for the company as a royalty management outfit – akin to that of its would-be acquirer, the New York-based Paul Royalty Fund – but this is not the only path it intends to pursue

That position, taken together with this latest deal, points to a possible future for the company as a royalty management outfit – akin to that of its would-be acquirer, the New York-based Paul Royalty Fund – but this is not the only path it intends to pursue

The Nasdaq OMX Group Inc., of New York, reported the semi-annual re-ranking of the Nasdaq Biotechnology Index, which will become effective prior to the market's open on May 20

In 2011, Clovis paid an undisclosed up-front fee to Pfizer Inc., of New York, plus potential milestones of $255 million, in exchange for the right to develop and commercialize the oral Poly(ADP-ribose) polymerase, or PARP, inhibitor, then in Phase I studies

Company (Location) Product Description Indication Status Date AUTOIMMUNE Biogen Idec Inc. (Weston, Mass.) DAC HYP A daclizumab high-yield process Multiple sclerosis Phase IIb data showed it reduced the annualized relapsed rate by 54%, meeting the study's primary endpoint 4/5/13 Fibrocell Science Inc. (Exton, Pa.) LaViv Autologous fibroblast injection azficel-T Moderate-to-severe acne scars Phase II study demonstrated that azficel-T treatment was associated with clinically meaningful improvement

Company (Location) Product Description Indication Status Date Actavis Inc. (Parsippany, N.J.) Testosterone Gel 1.62%, a generic version of AbbVie Inc.'s AndroGel 1.62% Absence of endogenous testosterone Filed an abbreviated NDA with the FDA 4/2/13 Almirall SA (Barcelona, Spain) and Forest Laboratories Inc. (New York) Aclidinium bromide and formoterol fumarate A long-acting muscarinic beta2 agonist and a long-acting beta2 agonist Chronic obstructive pulmonary disorder Top-line Phase III data